Roche Holding AG (SWX:ROG)
264.10
-1.00 (-0.38%)
Nov 6, 2025, 10:45 AM CET
Roche Holding AG Employees
Roche Holding AG had 103,249 employees as of December 31, 2024. The number of employees decreased by 356 or -0.34% compared to the previous year.
Employees
103,249
Change (1Y)
-356
Growth (1Y)
-0.34%
Revenue / Employee
614.90K CHF
Profits / Employee
91.32K CHF
Market Cap
227.23B
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 103,249 | -356 | -0.34% |
| Dec 31, 2023 | 103,605 | -8 | -0.01% |
| Dec 31, 2022 | 103,613 | 2,693 | 2.67% |
| Dec 31, 2021 | 100,920 | -545 | -0.54% |
| Dec 31, 2020 | 101,465 | 3,730 | 3.82% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Novartis AG | 75,883 |
| Alcon | 25,599 |
| Sandoz Group AG | 22,049 |
| Lonza Group AG | 18,944 |
| Sonova Holding AG | 18,366 |
| Straumann Holding AG | 11,815 |
| Galenica AG | 7,971 |
| Galderma Group AG | 6,545 |
Roche Holding AG News
- 2 days ago - Roche to present new data from its broad and innovative haematology portfolio at ASH 2025 - GlobeNewsWire
- 2 days ago - Genentech to Present New Data From Its Broad and Innovative Hematology Portfolio at ASH 2025 - Business Wire
- 2 days ago - Manifold Bio Announces Strategic Collaboration with Roche to Develop Multiple Next-Generation Brain Shuttles for Neurological Diseases - Business Wire
- 3 days ago - Positive phase III data for Roche's Gazyva/Gazyvaro show significant reduction in disease activity for systemic lupus erythematosus - GlobeNewsWire
- 3 days ago - Positive Phase III Data for Genentech's Gazyva Show Significant Reduction in Disease Activity for Systemic Lupus Erythematosus - Business Wire
- 3 days ago - Positive Phase III Data for Genentech's Gazyva Show Significant Reduction in Disease Activity for Systemic Lupus Erythematosus - Benzinga
- 3 days ago - Positive phase III data for Roche's Gazyva/Gazyvaro show significant reduction in disease activity for systemic lupus erythematosus - Benzinga
- 5 days ago - ALNY Q3 Earnings and Revenues Top Estimates on Higher Amvuttra Sales - Nasdaq